Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Gain (Loss) from Litigation Settlement
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainLossRelatedToLitigationSettlement.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — gain (loss) from litigation settlement.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — gain (loss) from litigation settlement?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — gain (loss) from litigation settlement of -$694K in Q1 2026.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — gain (loss) from litigation settlement?
- Over 2 years (2022 to 2024), Amneal Pharmaceuticals, Inc.'s affordable medicines — gain (loss) from litigation settlement has grown at a 107.8% compound annual growth rate (CAGR), from -$22.4M to -$96.69M.
- What does affordable medicines — gain (loss) from litigation settlement mean?
- Represents the net financial impact of legal settlements, judgments, or litigation-related awards recognized within the segment. This metric reflects non-recurring legal outcomes that can significantly impact segment profitability and operational cash flow.